Abstract
Activation of the stimulator of interferon genes (STING) pathway through cyclic dinucleotides (CDNs) has been explored extensively as potent vaccine adjuvants against infectious diseases as well as to increase tumor immunogenicity toward cancer immunotherapy in tumors. Despite the promise of CDNs as immune adjuvants, they suffer from several limitations: (1) CDNs exhibit fast clearance from the injection site, which may induce systemic toxicity, (2) naturally derived CDNs are susceptible to enzymatic degradation, which can lower the efficacy of adjuvanticity potential, and (3) CDNs have inefficient intracellular transport properties due to limited endosomal escape or reliance on the expression of a specific transporter protein. To address these challenges, over the last decade, a myriad of synthetic vehicles, including liposomes, polymers, and other nanoparticle platforms, have been developed to improve the bioavailability and therapeutic efficacy of STING agonists in preclinical mouse models. In this review, we will first summarize recent progress in the fundamental biology of the STING pathway in cancer and immunology, and then review advances in developing new STING agonist compounds and delivery strategies to overcome many challenges in the field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
